Literature DB >> 9253393

Cost-benefit analyses in the health-care literature: don't judge a study by its label.

K B Zarnke1, M A Levine, B J O'Brien.   

Abstract

OBJECTIVES: To assess whether health-care related economic evaluations labeled as "cost benefit analyses" (CBA) meet a contemporary definition of CBA methodology and to assess the prevalence of methods used for assigning monetary units to health outcomes. DATA SOURCES: Medline, Current Contents, and HSTAR databases and reference lists of review articles, 1991-1995. STUDY SELECTION: Economic analyses labeled as CBAs were included. Agreement on study selection was assessed. STUDY EVALUATION: CBA studies were classified according to standard definitions of economic analytical techniques. For those valuing health outcomes in monetary units (bona fide CBAs), the method of valuation was classified.
RESULTS: 53% of 95 studies were reclassified as cost comparisons because health outcomes were not appraised. Among the 32% considered bona fide CBAs, the human capital approach was employed to value health states in monetary units in 70%. Contingent valuation methods were employed infrequently (13%).
CONCLUSIONS: Studies labeled as CBAs in the health-care literature often offer only partial program evaluation. Decisions based only on resource costs are unlikely to improve efficiency in resource allocation. Among bona fide CBAs, the human capital approach was most commonly used to valuing health, despite its limitations. The results of health-care related CBAs should be interpreted with extreme caution.

Entities:  

Mesh:

Year:  1997        PMID: 9253393     DOI: 10.1016/s0895-4356(97)00064-4

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  17 in total

Review 1.  Willingness to pay and the valuation of programmes for the prevention and control of influenza.

Authors:  S Birch; A Gafni; B O'Brien
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 2.  Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.

Authors:  J Brown; M Sculpher
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 3.  Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

Authors:  E McIntosh; C Donaldson; M Ryan
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 4.  Cost effectiveness of continuing professional development in health care: a critical review of the evidence.

Authors:  C A Brown; C R Belfield; S J Field
Journal:  BMJ       Date:  2002-03-16

Review 5.  Willingness to pay as a measure of health benefits.

Authors:  M V Bala; J A Mauskopf; L L Wood
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.981

Review 6.  Trends in paediatric health economic evaluation: 1980 to 1999.

Authors:  W J Ungar; M T Santos
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

Review 7.  Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? : a critical review of published Korean economic evaluations.

Authors:  Kun-Sei Lee; Werner B F Brouwer; Sang-Il Lee; Hye-Won Koo
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications in Egypt.

Authors:  Samar Farid; Mahmoud Elmahdawy; Darin Baines
Journal:  Clin Drug Investig       Date:  2019-02       Impact factor: 2.859

Review 9.  Economic evaluations in shoulder pathologies: a systematic review of the literature.

Authors:  Ifedayo O Kuye; Nitin B Jain; Lauren Warner; James H Herndon; Jon J P Warner
Journal:  J Shoulder Elbow Surg       Date:  2011-08-23       Impact factor: 3.019

10.  Economics of public health programs for underserved populations: a review of economic analysis of the National Breast and Cervical Cancer Early Detection Program.

Authors:  Jaya S Khushalani; Justin G Trogdon; Donatus U Ekwueme; K Robin Yabroff
Journal:  Cancer Causes Control       Date:  2019-10-09       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.